Evidence map›Paper›PMID 36112186›Full record

ArticleRheumatology international2022

Efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study.

Dmytro Fedkov, Andrea Berghofen, Christel Weiss, Christine Peine, Felix Lang, Johannes Knitza, Sebastian Kuhn, Bernhard K Krämer, Jan Leipe

Open access · hybridAbstract read
In one paragraph

Article in Rheumatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Dmytro FedkovDepartment of Internal Medicine #3, Bogomolets National Medical University, Kiev, Ukraine. fedkovdmytro@gmail.com.ORCID 0000-0001-7965-9438
Andrea BerghofenMedical Clinic, Medical Faculty Mannheim of the University Heidelberg, Mannheim, Germany.ORCID 0000-0001-8306-0129
Christel WeissDepartment of Medical Statistics and Biomathematics, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer, Mannheim, Germany.ORCID 0000-0002-8692-5690
Christine PeineMidaia GmbH, Heidelberg, Germany.ORCID 0000-0001-6500-7180
Felix LangMidaia GmbH, Heidelberg, Germany.ORCID 0000-0001-6102-2674
Johannes KnitzaFriedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg, Erlangen, Germany.ORCID 0000-0001-9695-0657
Sebastian KuhnDepartment of Digital Medicine, Bielefeld University-Medical Faculty OWL, Bielefeld, Germany.ORCID 0000-0002-8031-2973
Bernhard K KrämerDepartment of Medicine (Nephrology, Rheumatology, Pneumology), University Hospital Mannheim, University of Heidelberg, HypertensiologyMannheim, Endocrinology, Germany.ORCID 0000-0002-1718-2918
Jan LeipeMedical Clinic, Medical Faculty Mannheim of the University Heidelberg, Mannheim, Germany.ORCID 0000-0001-9684-9700
Heidelberg University · DEBogomolets National Medical University · UAFriedrich-Alexander-Universität Erlangen-Nürnberg · DEJohannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EULAR highlighted the essential role of digital health in increasing self-management and improving clinical outcomes in patients with arthritis. The objective of this study was to evaluate the efficacy and safety of the digital health application (DHA) in patients with inflammatory arthritis. We assessed demographic parameters, treatment regimen, disease activity, and other patient-reported outcomes at baseline and after 4 weeks of DHA use added to standard care treatment. Of 17 patients, who completed the study, 7 (41.2%) patients were male, ranging from 19 to 63 (40.5 ± 12.2) years. No significant change in antirheumatic treatment was observed during the study. Statistically significant improvements (p < 0.05) were noted for health-related quality of life (increase in Physical Component Summary of Short Form-36 (SF-36) by 23.6%) and disease activity (decrease of Clinical Disease Activity Index and Simple Disease Activity Index by 38.4% and 39.9%, respectively). Clinically significant improvement was demonstrated for SF-36 Total Score (+ 14.4%), disease activity (Rheumatoid Arthritis Disease Activity Index- 5 to 15.9%), and depression (Patient Health Questionnaire- 9 to 13.5%). None of the efficacy parameters showed negative trends. No adverse events were reported throughout the study. The usability level was high i.e., the mean mHealth Application Usability Questionnaire Score of 5.96 (max.: 7.0) demonstrated a high level of application usability. This suggests that using a personalized disease management program based on DHA significantly improves several measures of patient-reported outcomes and disease activity in patients with inflammatory arthritis in a timely manner. These findings highlight the potential of complementary digital therapy in patients with inflammatory arthritis.

Indexed as

Arthritis, RheumatoidMobile ApplicationsFemaleHumansMalePilot ProjectsProspective StudiesQuality of LifeHealth-related quality of lifeHealthy lifestylemHealthMobile applicationsRheumatoid arthritisSpondyloarthritis

Identifiers

PMID36112186
PMCPMC9483251
OpenAlexW4296037715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.